主页文献库搜索
Autologous tumor-lysate pulsed dendritic cell vaccination, together with the ...

Prins(R M),Odesa(S),Soto(H),Yong(W H),Lai(... J Clin Oncol 0000-00-00

...mos. and median OS is 33.8 mos. This compares favorably to the published literature, with a median PFS of 6.9 mos and OS...

A randomized phase II study of BAY 43-9006 in combination with gemcitabine in...

Iqbal(S),Lenz(H J),Yang(D),Ramanathan(R K)... J Clin Oncol 0000-00-00

...mos (2.1 to 4.3) and 55 ± 0.08 in Arm B. Median OS and 6-mo OS were: 4.3 mos and 0.47 ± 0.13 in Arm A, and 6.5 mos and 0...

Interferon alpha + 13-cis-retinoic acid modulation of BCL-2 + paclitaxel for ...

Aisner(J),Dahlberg(S),Rodgers(J S),Aisner(... J Clin Oncol 0000-00-00

...mos; median OS is 6.4 mos (3.9-9.7 mos); median PFS is 2.3 mos (1.8-4.6 mos). 21 pts (62%) experienced worst degree toxi...

Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Result...

Chiarion-Sileni(V),Guida(M),Ridolfi(R),Rom... J Clin Oncol 0000-00-00

...mos in CTI and 21 in CDI arm. The median PFS and OS for all patients were 4 and 8.4 mos in CTI and 4 and 9.5 mos in CDI....

Gemcitabine (G) and cisplatin (C) in a modified 3-week schedule for non-small...

Caffo(O),Murgia(V),Ambrosini(G),Brugnara(S... J Clin Oncol 0000-00-00

...mos of median OS were observed. In metastatic pts the RR was 53% and the median OS was 11 mos.,it appears from our exper...

A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine,...

Khan(M I),Laber(D A),Chesney(J),Taft(B),Mi... J Clin Oncol 0000-00-00

...MOS is 8 months (1-25).,Addition of digoxin to bio-chemotherapy may have a synergistic anti-tumor effect on patients wit...

Complete surgical resection of residual melanoma metastasis and survival in s...

Taback(B),Honeyman(J),Liu(C),DeRaffele(G),... J Clin Oncol 0000-00-00

...mos for the entire group, but it has not yet been reached in patients achieving sCR after a mean follow-up of 31 mos (p<...

A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination w...

Kumar(S),Marks(R S),Richardson(R),Quevedo(... J Clin Oncol 0000-00-00

...mos after they go off treatment. The dose-escalation schema is in the table below.,Twelve pts (7 females, median age 63)...

Presurgical bevacizumab in patients with metastatic clear cell renal cell car...

Jonasch(E),Wood(C G),Matin(S),Tamboli(P),D... J Clin Oncol 0000-00-00

...mos (95% C.I,4.9-16.5). Sixteen pts died, with median OS of 25.4 mos (95% C.I.,13.3-Not Estimable). Common adverse event...

A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) wit...

Srinivasan(R),Choueiri(T K),Vaishampayan(U... J Clin Oncol 0000-00-00

...mos, respectively. Two pts have confirmed PRs and a third has PR pending confirmation. Five pts are too early to evaluat...

上一页 684 685 686 687 688 689 690 691 692 下一页 688 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]